Ozempic and Wegovy Benefits Tied to Dosage, Not Just Weight Loss, Studies Suggest
Three large studies published this year propose that the effectiveness of weight-loss drugs like Ozempic and Wegovy may be more closely linked to the dosage administered than to the amount of weight lost. Researchers from the biomedical research company nference analyzed electronic health records of tens of thousands of patients, splitting them by maximum dosage achieved and percentage of weight loss. In all three studies, focusing on mental health, cardiovascular health, and liver health, the results indicated that higher dosages correlated with better outcomes, independent of weight reduction.
One study, published in npj Metabolic Health and Disease, examined over 63,000 patients with documented neurological or psychiatric history. It found that patients reaching a dosage of 1.7 milligrams or higher had a significantly lower risk of substance use disorders and mood disorders compared to those on lower doses (0.25 to 1 mg). This benefit was not explained by weight loss alone.
Another study in npj Cardiovascular Health, involving nearly 47,000 patients with existing heart disease, found that while higher doses led to more weight loss, clinical benefits like reduced mortality were more strongly associated with the achieved dosage than the actual weight lost. Patients on high doses showed better outcomes than those on low doses, even if they lost the same percentage of weight.
A third study in npj Gut and Liver indicated improvements in liver stiffness markers, again showing a pattern linked to dosage. Separately, another large observational study linked these GLP-1 drugs to a roughly 40% reduction in asthma attacks and a 20% decrease in chronic obstructive pulmonary disease events. While these studies are observational and do not prove causation, the consistency across different bodily systems suggests a significant pattern.
Experts emphasize that these findings, if confirmed by controlled trials, could have implications for treatment decisions, particularly regarding cost. Many patients in Israel and elsewhere remain on lower doses due to side effects or cost, potentially foregoing some of the non-weight-related benefits. The researchers suggest that patients should discuss with their doctors whether staying on a particular dose might mean missing out on these additional therapeutic advantages.
